ALUR ALLURION TECHNOLOGIES, INC.

CIK 0001964979 37 ready 8-Ks latest May 27, 2026, 4:35 PM ET RSS · JSON

Ready 8-Ks 37

Latest filing May 27, 2026, 4:35 PM ET

Top materiality 0.85

Event mix other_material ×16 · regulatory ×7 · earnings ×7

Sentiment 6 pos · 14 neg · 17 neu

Latest earnings reported 2025-FY

Executive change recent →

Recent 8-K filings for ALUR

Highest-materiality recent filing

Allurion appeals NYSE delisting; trading moves to OTC; FDA approval of balloon catalyst for relisting plan

March 12, 2026, 7:59 PM ET other material materiality 0.85 negative item 3.01 item 8.01 item 9.01

NYSE notified Allurion on March 6, 2026 of delisting for failing to maintain $15M average global market cap over 30 consecutive days.
Trading suspended after March 6, 2026; common stock and warrants now trade on OTCID Market under ALUR and ALUR.WS.

Read filing →

May 27, 2026, 4:35 PM ET other material materiality 0.70 negative item 4.01 item 9.01

Allurion Technologies dismisses Deloitte & Touche, appoints CBIZ; discloses material weaknesses

Deloitte & Touche LLP dismissed as independent auditor effective May 22, 2026; Audit Committee approved.
March 12, 2026, 7:59 PM ET other material materiality 0.85 negative item 3.01 item 8.01 item 9.01

Allurion appeals NYSE delisting; trading moves to OTC; FDA approval of balloon catalyst for relisting plan

NYSE notified Allurion on March 6, 2026 of delisting for failing to maintain $15M average global market cap over 30 consecutive days.
March 2, 2026, 6:59 PM ET regulatory materiality 0.80 negative item 3.01 item 8.01 item 9.01

Allurion receives NYSE delisting notice for non-compliance with equity/market cap standard; intends to appeal

NYSE notified Allurion it fails Section 802.01B: requires ≥$50M stockholders' equity or ≥$50M market cap on 30-day average.
February 25, 2026, 6:59 PM ET other material materiality 0.60 neutral item 1.01 item 3.02 item 3.03 item 9.01

Allurion warrant inducement: $3M gross proceeds, exercise price cut to $1.15

Exercising holders purchase 2,659,565 shares at $1.15; Company expects $3.0M gross proceeds.
February 23, 2026, 6:59 PM ET regulatory materiality 0.85 positive item 7.01 item 9.01

FDA grants PMA approval for Allurion gastric balloon system for obesity

Allurion Smart Capsule approved for adults 22-65 with BMI 30-40 kg/m² after unsuccessful weight loss attempt.
January 12, 2026, 6:59 PM ET earnings materiality 0.65 positive item 2.02 item 9.01

Allurion Q4 revenue up 22-37% QoQ; FY2025 revenue ~$15M

Q4 2025 revenue $3.3-3.7M (22-37% QoQ increase); full-year revenue ~$15M.
December 19, 2025, 6:59 PM ET other material materiality 0.60 neutral item 5.07 item 9.01

Allurion stockholders approve reverse stock split, equity plan amendment, and other proposals at 2025 annual meeting

Re-elected directors Omar Ishrak, M.D., Douglas Hudson, and R. Jason Richey to serve until 2028 annual meeting.
November 12, 2025, 6:59 PM ET other material materiality 0.85 positive item 1.01 item 2.02 item 3.02 item 8.01 item 9.01

Allurion becomes debt-free via preferred equity exchange, raises $5M, Q3 revenue falls 50%

Exchanged all Notes and RIFA debt for Series B convertible preferred stock with $1,000 stated value, 8.25% dividend; company becomes debt-free.
August 14, 2025, 7:59 PM ET other material materiality 0.70 negative item 4.02

Allurion restates financials for 2023-2024 and Q1 2025 due to fair-value accounting errors

Non-reliance on prior financial statements for annual periods 2023-2024 and Q1 2025 due to RIFA and Notes fair value errors.
August 13, 2025, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 7.01 item 9.01

Allurion Q2 revenue plunges to $3.4M; restructure, potential restatement of non-cash items

Q2 2025 revenue $3.4M, down 71% YoY from $11.8M; gross margin 74% vs 76%.
August 7, 2025, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 2.05 item 7.01 item 9.01

Allurion cuts ~65% workforce, reports preliminary Q2 revenue ~$3M, shifts to GLP-1 combo therapy

Preliminary Q2 2025 revenue ~$3M, operating loss ~$7M, improved from $9.3M loss in Q2 2024; operating expenses down ~50% YoY.
May 14, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Allurion Q1 revenue $5.6M, net operating loss narrows 36% YoY; maintains FY 2025 guide

Q1 revenue of $5.6M (down 40% YoY); gross margin expanded to 75% from 73% YoY.
April 17, 2025, 7:59 PM ET other material materiality 0.85 negative item 1.01 item 3.02 item 9.01

Allurion amends notes; $5M converted at $3.35 as market cap falls below $15M

Second Amendment to Note Purchase Agreement with RTW Investments added conversion provisions triggered by sub-$15M market cap.
March 26, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Allurion Q4 revenue $5.6M, down 32% YoY; guides 2025 rev ~$30M, 50% opex cut

Q4 revenue $5.6M (down 32% YoY); full-year $32.1M; 2025 guidance ~$30M.
February 21, 2025, 6:59 PM ET other material materiality 0.70 neutral item 1.01 item 3.02 item 8.01 item 9.01

Allurion raises ~$6.1M via registered direct offering and private placement to fund GLP-1 clinical pipeline

Issued 900,000 shares of common stock at $5.23/share and 1,800,000 warrants (exercise $5.23, 5-year term, exercisable only after stockholder approval).
January 28, 2025, 6:59 PM ET other material materiality 0.65 negative item 1.01 item 3.02 item 8.01 item 9.01

Allurion raises ~$7.5M through registered direct offering and private placement of common stock and warrants

Gross proceeds of approximately $7.5 million from sale of 1,240,000 shares at $6.00 per share with accompanying warrants.
January 17, 2025, 6:59 PM ET other material materiality 0.60 neutral item 1.01 item 2.02 item 9.01 item 3.02

Allurion raises $2.5M via private placement; prelim Q4 rev $5.6M, FY rev ~$32M

Private placement of 841,751 shares at $2.97/share for gross proceeds of $2.5M; option for additional $10M.
January 8, 2025, 6:59 PM ET regulatory materiality 0.85 negative item 1.01 item 2.02 item 7.01 item 9.01

Allurion amends notes/RIFAs with cash & revenue covenants, FDA/France deadlines; reports AUDACITY trial topline results

Omnibus Amendment imposes minimum cash balances and minimum trailing 12-month revenue tested quarterly starting Q3 2025.
December 18, 2024, 6:59 PM ET other material materiality 0.65 neutral item 5.07 item 9.01

Allurion shareholders approve reverse stock split and share issuances at 2024 annual meeting

Class I directors re-elected: Shantanu Gaur, Krishna Gupta, Nicholas Lewin; votes for ranged 27.2M-33.7M.
November 13, 2024, 6:59 PM ET earnings materiality 0.85 negative item 2.02 item 9.01

Allurion Q3 revenue $5.4M, down 70% YoY; FY2024 guidance cut to $30-35M

Revenue $5.4M vs $18.2M prior year, includes $1.2M France recall charge; gross margin fell to 58% from 77%.
September 5, 2024, 7:59 PM ET regulatory materiality 0.75 negative item 3.01 item 7.01 item 9.01

Allurion receives NYSE notice for market cap non-compliance; stock to trade with ".BC"

NYSE notified Allurion avg market cap <$50M over 30 days ended Aug 29, 2024 and equity <$50M.
August 15, 2024, 7:59 PM ET regulatory materiality 0.70 negative item 3.01 item 7.01 item 9.01

Allurion receives NYSE deficiency notice for average stock price below $1.00

30-day average closing price below $1.00 as of Aug 8, 2024 triggered NYSE non-compliance notice.
August 13, 2024, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

Allurion Q2 revenue $11.8M, sequential +25%; French regulator suspends Balloon sales; FY guidance lowered to $40-45M

Q2 2024 revenue $11.8M, up 25% sequentially from Q1 but down from $13M in Q2 2023.
August 7, 2024, 7:59 PM ET regulatory materiality 0.85 negative item 8.01

Allurion Balloon sales suspended in France; device withdrawn pending remediation plan

French regulator ANSM suspended sales; Allurion withdrawing device from French market.
July 1, 2024, 7:59 PM ET other material materiality 0.70 neutral item 1.01 item 5.03 item 3.02 item 8.01 item 9.01

Allurion prices $20M public offering and $2.7M private placement with RTW

Public offering of 14.4M shares + warrants at $1.20/share for $17.3M gross; underwriters have 30-day option for 15% more.

Executive changes

Appointed

R. Jason Richey

Class II Director

ALUR · ALLURION TECHNOLOGIES, INC.

Effective: 2024-12-30
Filed: January 6, 2025, 6:59 PM ET

appointed R. Jason Richey to the Board as a Class II director

Role change (interim)

Shantanu Gaur

principal financial officer and principal accounting officer

ALUR · ALLURION TECHNOLOGIES, INC.

Effective: 2024-11-13
Filed: November 13, 2024, 6:59 PM ET

Shantanu Gaur, Chief Executive Officer of the Company, will serve as the Company’s principal financial officer and principal accounting officer, effective as of the close of business on November 13, 2024, until a replacement for Mr. Geberth is found.

Departed

Christopher Geberth

Chief Financial Officer

ALUR · ALLURION TECHNOLOGIES, INC.

Effective: 2024-11-13
Filed: November 13, 2024, 6:59 PM ET

Christopher Geberth, Chief Financial Officer of Allurion Technologies, Inc. (the “Company”), notified the Company of his decision to resign, effective as of the close of business on November 13, 2024, to pursue other interests.

Appointed

Keith Johns

Class III director

ALUR · ALLURION TECHNOLOGIES, INC.

Effective: 2024-09-02
Filed: September 4, 2024, 7:59 PM ET

On September 2, 2024, the Board of Directors (the "Board") of Allurion Technologies, Inc. ("Allurion" or the "Company") appointed Keith Johns to the Board as a Class III director to fill a vacancy created by an increase in the size of the Board from seven members to eight members, effective September 2, 2024.

Earnings & guidance

2025-FY EPS reported -$3.81 filing →

Materiality & sentiment trend

Max materiality 0.85 · Median 0.70 · Most common event other_material

6 positive 14 negative 17 neutral

source · ALUR on sec.gov